Label: ATOVAQUONE suspension
- NDC Code(s): 0121-0956-08
- Packager: PAI Holdings, LLC dba PAI Pharma
- Category: HUMAN PRESCRIPTION DRUG LABEL
- DEA Schedule: None
- Marketing Status: Abbreviated New Drug Application
Drug Label Information
Updated May 31, 2024
If you are a consumer or patient please visit this version.
- Download DRUG LABEL INFO: PDF XML
- Official Label (Printer Friendly)
-
HIGHLIGHTS OF PRESCRIBING INFORMATIONThese highlights do not include all the information needed to use ATOVAQUONE ORAL SUSPENSION safely and effectively. See full prescribing information for ATOVAQUONE ORAL SUSPENSION ...
-
Table of ContentsTable of Contents
-
1 INDICATIONS AND USAGE1.1 Prevention of - Pneumocystis jirovecii Pneumonia - Atovaquone oral suspension is indicated for the prevention of Pneumocystis jirovecii pneumonia (PCP) in adults and adolescents (aged 13 years ...
-
2 DOSAGE AND ADMINISTRATION2.1 Dosage for the Prevention of - P. jirovecii Pneumonia - The recommended oral dosage is 1,500 mg (10 mL) once daily administered with food. 2.2 Dosage for the Treatment of Mild-to-Moderate ...
-
3 DOSAGE FORMS AND STRENGTHSAtovaquone oral suspension USP is a bright yellow, tutti frutti flavored, oral suspension containing 750 mg of atovaquone per 5 mL. Atovaquone is supplied in 210-mL bottles.
-
4 CONTRAINDICATIONSAtovaquone oral suspension is contraindicated in patients who develop or have a history of hypersensitivity reactions (e.g., angioedema, bronchospasm, throat tightness, urticaria) to atovaquone or ...
-
5 WARNINGS AND PRECAUTIONS5.1 Risk of Limited Oral Absorption - Absorption of orally administered atovaquone oral suspension is limited but can be significantly increased when the drug is taken with food. Failure to ...
-
6 ADVERSE REACTIONSThe following adverse reactions are discussed in other sections of the labeling: Hepatotoxicity - [see - Warnings and Precautions (5.2)] . 6.1 Clinical Trials Experience - Because ...
-
7 DRUG INTERACTIONS7.1 Rifampin/Rifabutin - Concomitant administration of rifampin or rifabutin and atovaquone oral suspension is known to reduce atovaquone concentrations - [see Clinical Pharmacology (12.3)] ...
-
8 USE IN SPECIFIC POPULATIONS8.1 Pregnancy - Risk Summary - Available data from postmarketing experience with use of atovaquone in pregnant women are insufficient to identify a drug-associated risk for major birth defects ...
-
10 OVERDOSAGEOverdoses up to 31,500 mg of atovaquone have been reported. In one patient who also took an unspecified dose of dapsone, methemoglobinemia occurred. Rash has also been reported after overdose ...
-
11 DESCRIPTIONAtovaquone oral suspension USP is a quinone antimicrobial drug. The chemical name of atovaquone is - trans-2-[4-(4-chlorophenyl)cyclohexyl]-3-hydroxy-1,4-naphthalenedione. Atovaquone is a yellow ...
-
12 CLINICAL PHARMACOLOGY12.1 Mechanism of Action - Atovaquone is a quinone antimicrobial drug [see - Microbiology (12.4)]. 12.2 Pharmacodynamics - Relationship between Plasma Atovaquone Concentrations and Clinical ...
-
13 NONCLINICAL TOXICOLOGY13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility - Carcinogenicity studies in rats were negative; 24-month studies in mice (dosed with 50, 100, or 200 mg/kg/day), showed ...
-
14 CLINICAL STUDIES14.1 Prevention of PCP - The indication for prevention of PCP is based on the results of 2 clinical trials comparing atovaquone oral suspension with dapsone or aerosolized pentamidine in ...
-
16 HOW SUPPLIED/STORAGE AND HANDLINGAtovaquone oral suspension USP (bright yellow, tutti frutti flavored) containing 750 mg atovaquone per 5 mL. NDC 0121-0956-08: 210 mL bottle with child-resistant cap. Store at 15°C to 25°C (59°F ...
-
17 PATIENT COUNSELING INFORMATIONAdministration Instructions - Instruct patients to: Ensure the prescribed dose of atovaquone oral suspension is taken as directed. Take their daily doses of atovaquone oral suspension with food ...
-
PACKAGE LABEL.PRINCIPAL DISPLAY PANELNDC 0121-0956-08 - Atovaquone Oral Suspension USP - 750 mg/5 mL
-
INGREDIENTS AND APPEARANCEProduct Information